Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme by unknown
RESEARCH ARTICLE Open Access
Change of treatment guidelines and evolution
of ART initiation in rural South Africa: data of a
large HIV care and treatment programme
Mélanie PLAZY1,2*, François DABIS1,2, Kevindra NAIDU3, Joanna ORNE-GLIEMANN1,2, Till BARNIGHAUSEN3,4
and Rosemary DRAY-SPIRA5,6
Abstract
Background: While WHO recommendations are to treat people earlier and earlier, it will considerably increase the
number of HIV infected people eligible for antiretroviral therapy (ART). In South Africa, a country which carries one
of the highest HIV burden worldwide, very few studies are available on the impact of the ART guidelines on time to
ART initiation in both individuals with low CD4 count and those newly eligible for ART. We thus aimed to describe
ART initiation percentages in a large HIV programme in rural KwaZulu-Natal, South Africa, according to the
temporal changes of national ART eligibility guidelines from 2007 to 2012.
Methods: Adults who accessed the decentralized Hlabisa HIV treatment programme in 2007–2012 were included.
Three periods following the temporal change of ART eligibility guidelines were defined (Period 1: until April 2010;
Period 2: April 2010 - July 2011; Period 3: from August 2011). Percentages of ART initiation within three months of
programme entry were estimated in men, in women of childbearing age (<40 years old) and in older women, and
stratifying by CD4 count. Trend tests and logistic regression models were used to study the effects of change of
guidelines on ART initiation percentages.
Results: In individuals with CD4 count ≤200 cells/μL (N = 5709 men, N = 6743 women <40 years old and N = 2017
older women), percentages of ART initiation did not differ over time (p trend = 0.25; 0.28; and 0.14, respectively). In
individuals with CD4 count = 201–350 cells/μL (N = 2680 men, N = 6086 women <40 years old and N = 1415 older
women), percentages of ART initiation significantly increased over time (p trend <0.01 for the three groups): from
6 % in Period 1 to 20 % in Period 2 to 40 % in Period 3 in women of childbearing age, and from 7 % to 8-10 % to
42 % in men and in older women.
Conclusions: As temporal changes of guidelines, percentages of ART initiation significantly increased in newly ART
eligible people and did not decrease in individuals with very low CD4 counts. It will be crucial to continue verifying
the evolution of these percentages of ART initiation with future recommendations reaching near-to-universal access
to ART, to ensure that individuals most in need of ART receive it.
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Background
World Health Organization (WHO) guidelines for initi-
ating antiretroviral therapy (ART) have dramatically
evolved over the past decade. In 2002, ART were firstly
recommended for HIV-infected patients in moderate
and advanced stages of infection [1] with the aim to
limit disease progression and mortality [2–8]. It was
then strongly suggested that ART might be more effect-
ive if initiated earlier and in any case before advanced
HIV disease [9, 10]. With the evidence of less side-
effects, the expansion of ART recommendations was
thus suggested in 2006 and reinforced in 2010 for indi-
viduals with a CD4 count lower than 350 cells/μL, when
most people are still asymptomatic [11, 12]. It was finally
shown that ART can lower viral load in HIV-infected in-
dividuals [13] and decrease very significantly the risk of
HIV transmission within sero-discordant couples [14].
In 2013, WHO guidelines have thus suggested to expand
the ART eligibility criteria at CD4 count <500 cells/μL
[15]. As WHO recommendations are to treat earlier and
earlier in the course of the HIV infection, it is thus crit-
ical to inform public health decision-makers of the
impact of recommendations changes on time to ART
initiation. Specifically, it is important to verify that the
time to ART initiation in people with low CD4 count is
not longer as the number of newly ART eligible people
is increasing with expanded recommendation, and that
people who become eligible with higher CD4 count initi-
ate ART quickly even if they do not feel sick [16].
In South Africa, a country which carries one of the
highest HIV burden worldwide, with an estimated 6.3
million people who were living with HIV in 2013 with
an HIV prevalence equal to 19.1 % in adults aged 15–49
years old [17], recommendations regarding ART eligi-
bility have followed WHO guidelines with some delay
[18, 19]. Although ART coverage dramatically in-
creased these last years in South Africa [20], many in-
dividuals eligible for ART were not on treatment in 2012
[21]. In order to better prepare the implementation and
the consequences of the new WHO recommendations, we
thus aimed to describe ART initiation percentages in a
large decentralized HIV programme in rural KwaZulu-
Natal, South Africa, according to the temporal changes of
national ART eligibility guidelines from 2007 to 2012.
Methods
Study setting
The decentralized Hlabisa HIV Treatment and Care
Programme was initiated in mid-2004 in southern
uMkhanyakude district in northern KwaZulu-Natal [22].
This programme takes place in a poor, predominantly
rural area, where adult HIV prevalence was about 29 %
in 2011, peaking at more than 45 % in women between
25 and 49 year old and almost 30 % in men of the same
age [23]. This programme is a partnership between the
local Department of Health and the Africa Centre for
Health and Population Studies. It is devolved to the 17
primary health care clinics in the sub-district, and is
nurse- and counsellor-led. People can access HIV testing
and counselling at any time and receive ART for free if
they are eligible. Blood samples are taken from people
who are diagnosed HIV-positive on rapid test at the
clinic and are sent to the local laboratory at Hlabisa dis-
trict hospital for CD4 testing, with results available at
the clinic-level within one week of HIV test. ART eligi-
bility has been assessed according to the SA national
guidelines: CD4 count ≤200 cells/μL or WHO stage IV
until April 2010; expansion to CD4 count ≤350 cells/μl
for people with tuberculosis (TB) and pregnant women
from April 2010 [18]; and further expansion to all adults
with CD4 count ≤350 cells/μl from August 2011 as per
the 2010 WHO guidelines [12]. Before initiating ART,
eligible patients attend three ART literacy sessions
within a two-week period during which they are also fur-
ther assessed clinically. Individuals not yet eligible for
ART are encouraged to return to the clinic for subse-
quent monitoring, after one year if CD4 count >500
cells/μL and after six months if CD4 count ≤500 cells/
μL. Clinical and laboratory information of both ART-
eligible and not-yet ART eligible individuals who
accessed one of the 17 primary health care clinics in-
cluded within this programme are routinely collected
and entered in a dedicated database (named ARTemis).
Available data
Within the ARTemis database, very few data were avail-
able for individuals not on ART: information concerning
sex and age was collected at the first clinic visit, and
CD4 count was collected at each clinic visit. Information
on death and transfer was reported over time in clinics;
data on death were completed through linkage with the
National Population Register performed in October 2011.
Study population
For this analysis, all adults ≥16 years old who entered the
programme between January 1st, 2007 and September
15th, 2012 were included. Entry in the programme was
assessed as the date of the first CD4 measure following
HIV diagnosis. Individuals were excluded if they were
transferred in from outside the Hlabisa programme, if
information on sex or first clinic visit was missing, or if
the first CD4 count measure was unknown.
Statistical analysis
Our main outcome was ART initiation within three
months of programme entry, according to the cut-off
suggested by Fox et al. for studying uptake of ART initi-
ation after ART eligibility [24]. Analyses were restricted to
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participants eligible for ART initiation according to the
most recent South African recommendations in our study
period, i.e. all individuals with ≤350 cells/μL at
programme entry. As pregnancy is an important charac-
teristic for defining ART eligibility (and as the last national
antenatal sentinel HIV report [25] suggested that the large
majority of women of childbearing age were <40 years old
in South Africa) , three groups of individuals were consid-
ered: i/ men, ii/ women of childbearing age (less than
40 years old), iii/ older women (40 years or older); these
groups were additionally stratified according to baseline
CD4 count level (0–200 cells/μL; 201–350 cells/μL).
Three entry periods were also defined, categorized accord-
ing to the changes in ART eligibility criteria over time:
period 1 from January 2007 to March 2010, period 2 from
April 2010 to July 2011, and period 3 since August 2011.
For each of the groups of individuals, and after stratifica-
tion by CD4 count, percentages of ART initiation within
the three months following entry in the programme were
globally compared across these three entry periods using
trend tests; we then performed univariate logistic regres-
sion models for estimating the specific impact of change
of guidelines on ART initiation percentages. Individuals
who died within the three months following entry in the
programme and before ART initiation were excluded.
Analyses were carried out using STATA version 11.2
(StataCorp, College Station, Texas).
Ethics statement
Ethical approval for this analysis of anonymized data
from the HIV Treatment and Care Programme was ob-
tained from the University of KwaZulu-Natal (BE066/07)
and granted by the Research Office of the KwaZulu-
Natal Department of Health, and re-certified annually.
Results
Study population
Overall, 44,503 adults entered the HIV Hlabisa programme
between January 1, 2007 and September 15, 2012. Among
them, 3,552 were excluded from the analysis, of whom
2,544 were patients transferred in from another HIV
programme, 730 had a date of first clinic visit before the
date of first CD4 count measurement and 15 had a missing
clinic name; the others reasons for exclusion were because
information on sex was unknown (N = 247), and results of
the first CD4 measure was unknown (N = 16).
Of the remaining 40,951 patients, 24,082 entered the
HIV programme in period 1, 8,535 in period 2 and 8,334
in period 3. Among all these individuals, the proportion
of women <40 years old remained stable across the three
entry periods (56-57 %), the proportion of men increased
from 27.6 % during period 1 to 31.0 % during period 3
whereas the proportion of women ≥40 years old de-
creased from 14.9 % to 12.8 % (p < 0.001) (Table 1).
Overall, 11,865 men, 23,399 women <40 years old and
5,687 women ≥40 years old accessed the HIV programme
across the three entry periods. For these three groups of
individuals, baseline median CD4 cell count significantly
increased between period 1 and period 3 (p < 0.001 for all
groups): from 180 cells/μL [Inter-Quartile Range (IQR)
71–341] to 229 cells/μL [IQR 100–386] in men, from 307
cells/μL [IQR 164–481] to 349 cells/μL [IQR 213–520] in
women <40 years old and from 258 cells/μL [IQR 135–
432] to 333 cells/μL [IQR 161–522] in women ≥40 years
Table 1 Description of included individuals according to entry period
Period 1 Period 2 Period 3 P*
Group–n (%)
Men 6,643 (27.6) 2,640 (30.9) 2,582 (31.0) <0.001
Women < 40 years old 13,851 (57.5) 4,867 (57.0) 4,681 (56.2)
Women ≥40 years old 3,588 (14.9) 1,028 (12.1) 1,071 (12.8)
CD4 count (cells/μL) - median [IQR]
In men 180 [71–341] 183 [74–335] 229 [100–386] <0.001
In women <40 years old 307 [164–481] 288 [158–458] 349 [213–520] <0.001
In women ≥40 years old 258 [135–432] 242 [119–419] 333 [161–522] <0.001
Age (years)-median [IQR]
In men 36.5 [30.4-44.5] 34.8 [28.7-43.0] 34.5 [28.3-42.0] <0.001
In women <40 years old 27.5 [23.4-32.6] 26.5 [22.5-31.2] 26.7 [22.4-31.6] <0.001
In women ≥40 years old 46.8 [43.2-51.9] 46.9 [42.9-53.0] 48.0 [43.7-53.4] <0.001
IQR: Inter-Quartile Interval
Period 1: January 1, 2007–March 31, 2010; Period 2: April 1, 2010–July 31, 2011; Period 3: August 1, 2011–September 15, 2012
* p.value with Chi2 tests (for group) or Anova tests (for CD4 cells count and Age)
HIV Hlabisa programme, KwaZulu-Natal, South Africa. 2007–2012
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old (Table 1). Median age at programme entry varied also
according to entry period (p < 0.001 for all groups)
(Table 1).
Evolution of ART initiation percentages within three
months of entry programme, stratified by group and
CD4 count
In total, 6,156 men, 7,045 women <40 years old and
2,153 women ≥40 years old had a CD4 count ≤200 cells/
μL at programme entry. Among them, respectively
7.2 %, 4.3 % and 6.3 % died before ART within three
months of programme entry and were thus excluded
from the analysis (Fig. 1). Overall percentages of ART
initiation within the three months following programme
entry among individuals with CD4 count ≤200 cells/μL
were 53.8 % [95 % Confidence Interval: 52.6 %-55.2 %]
in men (N = 5,709), 48.8 % [47.6 %-50.0 %] in women
<40 years old (N = 6,743) and 57.4 % [55.2 %-59.6 %] in
women ≥40 years old (N = 2,017). ART initiation per-
centages varied slightly between period 1 and period 3,
from 53.8 % [52.1 %-55.5 %] to 56.8 % [53.9 %-59.6 %] in
men, from 48.3 % [46.7 %-49.8 %] to 49.9 % [46.9 %-
52.9 %] in women <40 years old, and from 58.1 %
[55.3 %-60.7 %] to 52.3 % [46.9 %-57.8 %] in women
≥40 years old (Fig. 2), without significant tendencies
according to period entry (p trend = 0.25 in men; p
trend = 0.28 in women <40 years old and p trend = 0.14
in women ≥40 years old) (Fig. 2); among these three
groups, the odds of ART initiation did not differ be-
tween period 2 compared to period 1 or between period
3 compared to period 1 (Table 2).
In total, 2,719 men, 6,126 women <40 years old and
1,423 women ≥40 years old had a CD4 count between
201 and 350 cells/μL at entry in the programme. Among
them, respectively 1.4 %, 0.6 % and 0.6 % died before
ART within three months of entry programme and were
thus excluded from the analysis (Fig. 1). Overall percent-
ages of ART initiation within three months of programme
entry among individuals with CD4 count between 201 and
350 cells/μL were 16.2 % [14.9 %-17.7 %] in men (N =
2,680), 16.0 % [15.1 %-16.9 %] in women <40 years old
(N = 6,086) and 13.1 % [11.4 %-14.9 %] in women
≥40 years old (N = 1,415). ART initiation percentages
significantly increased over time in the three groups
(p trend <0.001 in all the groups, Fig. 2), but at a dif-
ferent pace. In women ≥40 years old and in men, per-
centages of ART initiation within the three months
following programme entry slightly increased between
period 1 and period 2 (from 6.9 % [5.5 %-8.7 %] to 8.4 %
[5.5 %-12.5 %], Odd-Ratio [OR] 1.23; 95 % Confidence
Interval [95 % CI] 0.74-2.06; and from 6.9 % [5.7 %-8.3 %]
to 10.3 % [8.1 %-13.0 %], OR 1.56; 95 % CI 1.12-2.17,
respectively (Fig. 2, Table 2)); and then dramatically
increased to 41.7 % [35.6 %-48.0 %] and 41.8 % [38.1 %-
45.6 %], respectively, during period 3 (compared to period
1, OR 9.61; 95 % CI 6.70-13.79 and OR 9.73; 95 % CI
7.52-12.59, respectively (Fig. 2, Table 2)). In women
<40 years old, percentages of ART initiation within the
three months following programme entry showed a
marked increase between period 1 and period 2, from
6.0 % [5.3 %-6.9 %] to 20.0 % [18.0 %-22.3 %] (OR 3.90;
95 % CI 3.21-4.73); and then further increased to 39.6 %
[36.9 %-42.3 %] during period 3 (compared to period 1,
OR 10.19; 95 % CI 8.53-12.19) (Fig. 2, Table 2).
Discussion
In this rural area of South Africa, as guidelines regarding
ART eligibility criteria have been expanded, percentages
of ART initiation within three months of programme
entry have clearly increased for individuals eligible for
Fig. 1 Inclusion of individuals according to sex and CD4 cell count. HIV Hlabisa programme. KwaZulu-Natal, South Africa. 2007–2012
PLAZY et al. BMC Infectious Diseases  (2015) 15:452 Page 4 of 8
ART according to new criteria (CD4 count equal to
201–350 cells/μL), without decreasing for individuals
with very low CD4 count (CD4 count lower than 200 cells/
μL). Evolution of ART initiation percentages matched the
expansion of ART eligibility guidelines in individuals with
a baseline CD4 count comprised between 201 and 350
cells/μL. In women of childbearing age, ART initiation
percentages significantly gradually increased during the
three study periods. In men and in women ≥40 years old, a
slight increase was observed between the first and the sec-
ond period (when ART eligibility criteria was also ex-
panded to TB co-infected individuals with a CD4 count
≤350 cells/μL), but this increase in ART initiation percent-
ages was most important between the second and the third
Fig. 2 Percentages of ART initiation for each groups (men, women <40 years old, women ≥40 years old), stratified by CD4 count level and entry
period. HIV Hlabisa programme. KwaZulu-Natal, South Africa. 2007–2012
Table 2 ART initiation according to period entry in surviving men, women <40 years old and women ≥40 years old
Men Women <40 years old Women ≥40 years old
N ART initiation N ART initiation n ART initiation
% OR* 95 % CI % OR* 95 % CI % OR* 95 % CI
CD4 = 0–200 cells/μL
Entry period
Period 1 3 251 53.8 1.00 - 4 136 48.3 1.00 - 1 290 58.1 1.00 -
Period 2 1 324 51.4 0.91 0.80-1.03 1 537 49.3 1.04 0.93-1.17 408 59.3 1.05 0.84-1.32
Period 3 1 134 56.8 1.13 0.98-1.29 1 070 49.9 1.07 0.93-1.22 319 52.3 0.79 0.62-1.01
CD4 = 201–350 cells/μL
Entry period
Period 1 1 411 6.9 1.00 - 3 524 6.0 1.00 - 925 6.9 1.00 -
Period 2 611 10.3 1.56 1.12-2.17 1 297 20.0 3.90 3.21-4.73 250 8.4 1.23 0.74-2.06
Period 3 658 41.8 9.73 7.52-12.59 1 265 39.6 10.19 8.53-12.19 240 41.7 9.61 6.70-13.79
Period 1: January 1, 2007–March 31, 2010; Period 2: April 1, 2010–July 31, 2011; Period 3: August 1, 2011–September 15, 2012
OR: Odd-Ratio; 95 % CI: 95 % Confidence Interval
* Logistic regression
HIV Hlabisa Programme, KwaZulu-Natal, South Africa. 2007–2012
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entry period (when all individuals with a CD4 count ≤350
cells/μL became eligible for ART). These results remained
unchanged when adjusted for age (data not shown).
A previous modelling study showed that the number
of people eligible for ART in South Africa increased
from 1.7 million to 2.6 million after the change of ART
eligibility criteria from CD4 ≤ 200 cells/μL to CD4 ≤ 350
cells/μL [26]. Our results from a rural South African
study area suggest that the HIV programme, with the
funding available at this time (PEPFAR/USAID and the
KZN Department of Health), could adapt on the field to
the change of national guidelines, with a number of indi-
viduals accessing clinics for initiating ART that increased
over time and with higher CD4 count at the date of
ART initiation as showed in a previous analysis [27].
It has then been estimated that expanding the ART
eligibility criteria to CD4 ≤ 500 cells/μL would dramatic-
ally increase the number of individuals eligible for ART
to 4.1 million countrywide [26]. Thus, the true test of
the impact of the change of guidelines will be with the
evaluation of the implementation of the 2013 WHO
guideline that has begun in January 2015 in South Africa
(http://www.iol.co.za/news/politics/hiv-drugs-treatment-
to-start-earlier-motsoaledi-1.1724412#.VDuOLRbH-ZT),
and especially within the Hlabisa sub-district where the
HIV care and treatment programme is, since 2013, only
funded by the KwaZulu-Natal Department of Health.
In spite of the positive trends in ART initiation, the
proportion of eligible individuals who initiated ART
remained far from optimal. Indeed, during entry period
3, and for both men and women, percentages of ART
initiation within three months of programme entry were
<60 % in individuals with a CD4 count ≤200 cells/μL
and <50 % in those with a CD4 count between 201 and
350 cells/μL. This is consistent with previous studies con-
ducted in this setting [28] as well as in other sub-Saharan
African contexts [29–31] that showed that ART initiation
percentages significantly decreased with increasing CD4
cell counts; some authors suggest that the perception of
being or feeling sick can be associated with ART initiation
[32, 33]. While WHO recommendations aim to treat more
people earlier in the course of the HIV infection [15], these
results observed in a region of high HIV prevalence sug-
gest that it will be crucial to develop interventions to fur-
ther increase ART initiation percentages in all ART-eligible
patients. It has been suggested that involvement of com-
munity health workers may be helpful for increasing ART
scale up among individuals eligible while they are still
asymptomatic [34]. It has also been shown that the devel-
opment of the CD4 point-of-care strategy – that reduces
the numbers of visits in clinics–could increase retention of
patients in HIV care and ART initiation percentages [35–
37]. Finally, home-based ART initiation seems to be effect-
ive for increasing ART initiation percentages [38]; a study
also suggested that the home-based HIV and ART care
strategy is not associated with negative patient outcomes
[39].
Although this study is based on data of a large HIV
treatment and care programme, some individuals may
have initiated ART outside the programme, which may
have led to an underestimation of the ART initiation
percentages. However, this bias is likely to be limited
since the Hlabisa HIV programme is decentralized in
primary health care clinics with relatively easy access
and this area is rural and poor, making it difficult for
people to access ART somewhere else. Another limita-
tion is that among included participants, some people
may have failed to return to the clinic to receive their
CD4 count result after HIV testing and thus were un-
aware of their status regarding ART eligibility [40–44];
however we cannot provide a precise figure as this infor-
mation was not collected in the database. Moreover, we
were able to update in October 2011 the mortality figure
through linkage with the National Population register.
Mortality estimates are thus probably more robust in Pe-
riods 1 and 2 compared to Period 3; as death was an ex-
clusion criteria when estimating percentages of ART
initiation, it is possible that these percentages were
underestimated in Period 3. Lastly, WHO stage and
pregnancy were not available in the database for people
not on ART; we only considered sex and age for defining
the three groups of individuals on which we described
the evolution of ART initiation percentages.
Conclusion
In conclusion, the percentages of ART initiation signifi-
cantly increased in individuals newly eligible for ART
after ART eligibility criteria expansion, without decreasing
in individuals with advanced disease. However, these per-
centages of ART initiation remained low three months
after programme entry. While future recommendations
aim at reaching near-to-universal access to ART, it will be
crucial to continue verifying the evolution of ART
initiation percentages according to these new recom-
mendations, as well as intensifying efforts in order to
rapidly maximize ART initiation after accessing an
HIV programme in all individuals eligible for ART,
whether they are at an advanced stage of HIV infec-
tion or not.
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